Key result
Elevated small dense LDL-C strongly predicts ASCVD onset and recurrence, particularly in type 2 diabetes.
Why the study?
LDL-C has limited utility as a predictive biomarker for ASCVD in type 2 diabetes, where triglyceride levels are typically elevated without marked LDL-C increases.
Does sdLDL-C measurement improve the prediction of atherosclerotic cardiovascular disease compared to standard LDL-C in patients with type 2 diabetes?
Does sdLDL-C measurement improve the prediction of atherosclerotic cardiovascular disease compared to standard LDL-C in patients with type 2 diabetes?
Measuring sdLDL-C offers superior ASCVD risk stratification over standard LDL-C in type 2 diabetes due to its strong association with insulin resistance and hypertriglyceridemia.
Low-density lipoprotein cholesterol (LDL-C) is known to be a causal substance of atherosclerosis, but its usefulness as a predictive biomarker for atherosclerotic cardiovascular disease (ASCVD) is limited. In patients with type 2 diabetes (T2D), LDL-C concentrations do not markedly increase, while triglycerides (TG) concentrations are usually elevated. Although TG is associated with ASCVD risk, they do not play a direct role in the formation of atheromatous plaques. TG changes the risk of ASCVD in a way that is dependent on LDL-C, and TG is the primary factor in reducing LDL particle size. Small dense (sd)LDL, a potent atherogenic LDL subfraction, best explains the "Atherogenic Duo" of TG and LDL-C. Although hypertriglyceridemia is associated with small-sized LDL, patients with severe hypertriglyceridemia and low LDL-C rarely develop ASCVD. This suggests that quantifying sdLDL is more clinically relevant than measuring LDL size. We developed a full-automated direct sdLDL-C assay, and it was proven that sdLDL-C is a better predictor of ASCVD than LDL-C. The sdLDL-C level is specifically elevated in patients with metabolic syndrome and T2D who have insulin resistance. Due to its clear link to metabolic dysfunction, sdLDL-C could be named "metabolic LDL-C." Insulin resistance/hyperinsulinemia promotes TG production in the liver, causing steatosis and overproduction of VLDL1, a precursor of sdLDL. sdLDL-C is closely associated with steatotic liver disease and chronic kidney disease, which are common complications in T2D. This review focuses on T2D and discusses the clinical significance of sdLDL-C including its composition, pathophysiology, measurements, association with ASCVD, and treatments.
No takes yet. Share an insight, caveat, or question.
Tsutomu Hirano (2025) conducted a review in Type 2 diabetes and dyslipidemia. Elevated small dense LDL-C (sdLDL-C) was evaluated. Small dense LDL-C is a potent atherogenic subfraction linked to metabolic dysfunction and serves as a highly sensitive biomarker for predicting ASCVD onset and recurrence, particularly in type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: